26 Aug 2026 (Navroze Bureau) : Scientists at the Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR), Bengaluru, have developed a smartphone-enabled platform that could make the detection of a key Alzheimer’s disease biomarker more accessible and affordable.
The technology, called ADxFluor, uses a novel fluorescent probe named TZ-48 to detect amyloid-beta (Aβ), a protein closely associated with Alzheimer’s disease.
How the Smartphone Technology Works
The platform combines the TZ-48 probe with a smartphone-based detection system.
When TZ-48 interacts with amyloid-beta, its fluorescence intensity and lifetime change. These changes can be captured and quantified through a dedicated smartphone application, allowing researchers to measure Aβ levels rapidly.
Amyloid-Beta Is a Key Alzheimer’s Biomarker
Alzheimer’s disease is associated with the abnormal aggregation of amyloid-beta peptides into fibrils and plaques in the brain.
Because Aβ pathology can appear early in the disease process, detecting and measuring the biomarker is an important area of Alzheimer’s research.
Probe Shows Promising Laboratory Results
The JNCASR researchers found that TZ-48 binds strongly to amyloid-beta fibrils and has a reported detection limit of 68 nanomolar.
The probe also showed the ability to cross the blood-brain barrier and label amyloid-beta plaques in genetically modified mouse models of Alzheimer’s disease.
Blood and CSF Detection Also Demonstrated
The research went beyond brain-tissue imaging.
TZ-48 was also used to detect amyloid-beta in cerebrospinal fluid (CSF) and blood serum. In experiments involving mice, the researchers reported that the system could distinguish Alzheimer’s-disease models from healthy animals based on serum Aβ measurements.
ADxFluor Could Improve Accessibility
Current Alzheimer’s biomarker testing can involve expensive imaging systems, specialised laboratories and trained personnel.
The researchers say the smartphone-integrated approach could potentially offer a portable, low-cost and user-friendly alternative for biomarker screening and disease staging.
From Laboratory Research to Point-of-Care Testing
The development is particularly significant because it combines molecular detection with smartphone technology.
Instead of relying entirely on specialised laboratory instruments to quantify fluorescence, ADxFluor is designed to use a smartphone application to process the fluorescence response of TZ-48 and provide a rapid assessment of serum Aβ levels.
Study Published in ACS Chemical Neuroscience
The research was published in ACS Chemical Neuroscience in June 2026 and appeared in the journal’s August 2026 issue.
The study involved researchers from JNCASR, including Krithi K. Bhagavath, Madhu Ramesh, Yogendra Kumar, Sabyasachi Mandal, Hiriyakkanavar Ila and Thimmaiah Govindaraju.
Technology Still Needs Clinical Validation
Despite the promising findings, the platform should not yet be considered a replacement for established clinical diagnostic methods.
Much of the reported validation was conducted in laboratory and mouse-model studies. Further research and clinical testing in humans will be needed to establish its accuracy, reliability and usefulness in routine Alzheimer’s diagnosis.
Potential for Wider Screening
If future clinical studies confirm its performance, a smartphone-based biomarker platform could help make Alzheimer’s screening more accessible, particularly in settings where expensive imaging equipment and specialised facilities are difficult to access.
The JNCASR work therefore represents an important step toward developing more portable approaches to neurological disease assessment.